Eterna Therapeutics (ERNA) 10-Q2024 Q3 Quarterly report

Filed: 12 Nov 24, 5:16pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: accelerated, accessible, accredited, addendum, Anderson, antitumor, Bio, breast, bridge, bring, buy, cancelled, Center, comprised, concurrent, cytokine, deadline, ELOC, exempt, exposure, extinguished, extinguishment, facilitate, feature, fulfill, gain, innovative, input, intrinsic, lead, MD, mesenchymal, microenvironment, mission, multiplied, multiplying, nearest, negative, opening, ovarian, paragraph, percent, person, potent, premium, proforma, quantity, ratio, reacquired, reacquisition, recognition, remuneration, Rheumatoid, rounded, scale, shareholder, slip, solicitation, soliciting, Somverville, SPA, submission, suspended, suspension, thirty, TME, triple, tumor, twenty, uncured, University, unleashing, vision, yearly

Removed: abnormal, acid, allogeneic, annum, anticipate, antidilution, antigen, attack, brain, capable, chemical, chimeric, clonal, constrained, conventional, correcting, coverage, covering, create, cumulative, defending, degenerative, delete, deploying, differentiated, disease, DNA, durable, editing, efficiency, efficient, embedded, employ, encoding, endosomal, enforcing, entrapment, epigenetic, episomal, evident, exceed, expanded, expensive, expression, extended, eye, fight, foot, fragment, gene, generation, genetic, genome, genomic, GvHD, hand, host, human, immunoregulatory, improvement, inactivate, individually, infection, insert, inserted, insertion, insertional, key, leave, leaving, leukocyte, licensing, limit, lipid, living, loci, low, lung, making, mechanism, membrane, modulating, nanoparticle, NoveSliceTM, nucleic, patient, performing, pipeline, plasma, platform, portfolio, prevent, preventing, primary, proceeding, prosecuting, protein, pursuit, qualified, random, ratchet, realizing, receptor, reduced, regenerative, render, Renewal, rentable, repair, reprogrammed, reprogramming, resistant, reversal, science, seek, select, Sendai, SEPA, skin, specialist, stage, stealth, substance, suffer, system, tenant, threat, TIA, ToRNAdoTM, transformational, translation, transplanted, treatment, typically, UltraSliceTM, unwanted, uptake, vector, vivo

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ERNA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Eterna Therapeutics Inc. for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge on the date hereof:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Eterna Therapeutics Inc. for the period presented therein.

Date: November 12, 2024	/s/ Sanjeev Luther
	Sanjeev Luther
	President and Chief Executive Officer
	(Principal Executive Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Report or as a separate disclosure document.